Huadong Medicine Financials
| 000963 Stock | 35.95 0.24 0.66% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 4 B | 3.8 B |
|
|
Huadong | Select Account or Indicator |
Understanding current and past Huadong Medicine Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Huadong Medicine's financial statements are interrelated, with each one affecting the others. For example, an increase in Huadong Medicine's assets may result in an increase in income on the income statement.
Please note, the presentation of Huadong Medicine's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Huadong Medicine's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Huadong Medicine's management manipulating its earnings.
Huadong Medicine Stock Summary
Huadong Medicine competes with Industrial, Kweichow Moutai, Agricultural Bank, China Mobile, and China Construction. Huadong Medicine is entity of China. It is traded as Stock on SHE exchange.Specialization | Health Care, Drug Manufacturers - Specialty & Generic |
| Instrument | China Stock View All |
| Exchange | Shenzhen Stock Exchange |
| ISIN | CNE0000011S1 |
| Business Address | No 866 Moganshan |
| Sector | Health Care Providers & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.eastchinapharm.com |
| Phone | 86 571 8990 3388 |
You should never invest in Huadong Medicine without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Huadong Stock, because this is throwing your money away. Analyzing the key information contained in Huadong Medicine's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Huadong Medicine Key Financial Ratios
Huadong Medicine's financial ratios allow both analysts and investors to convert raw data from Huadong Medicine's financial statements into concise, actionable information that can be used to evaluate the performance of Huadong Medicine over time and compare it to other companies across industries.| Revenue | 40.62 B | ||||
| Gross Profit | 12.03 B | ||||
| EBITDA | 4.62 B | ||||
| Net Income | 2.84 B | ||||
| Total Asset | 33.51 B |
Huadong Medicine Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 21.5B | 24.2B | 27.0B | 31.2B | 33.5B | 35.2B | |
| Other Current Liab | 1.4B | 1.8B | 2.0B | 2.3B | 16.0M | 15.2M | |
| Other Liab | 397.3M | 200.7M | 236.6M | 569.4M | 654.8M | 687.6M | |
| Retained Earnings | 8.4B | 10.7B | 12.6B | 13.5B | 15.7B | 16.5B | |
| Accounts Payable | 4.4B | 4.5B | 4.5B | 5.9B | 6.1B | 6.4B | |
| Cash | 2.4B | 3.2B | 4.0B | 4.0B | 4.7B | 4.9B | |
| Other Assets | 356.7M | 334.3M | 876.5M | 1.1B | 1.2B | 1.3B | |
| Net Receivables | 6.9B | 6.1B | 7.2B | 7.2B | 7.5B | 7.8B | |
| Inventory | 4.0B | 4.1B | 4.0B | 4.5B | 4.3B | 4.5B | |
| Other Current Assets | 425.7M | 336.2M | 316.0M | 582.3M | 59.9M | 56.9M | |
| Total Liab | 8.6B | 9.0B | 10.1B | 12.0B | 11.9B | 12.5B | |
| Intangible Assets | 1.5B | 1.5B | 2.2B | 2.9B | 3.3B | 3.5B | |
| Long Term Debt | 48.1M | 151.6M | 139.2M | 1.1B | 520.8M | 489.6M | |
| Net Tangible Assets | 7.0B | 9.4B | 11.7B | 12.2B | 14.0B | 9.0B | |
| Short Long Term Debt | 655.5M | 1.4B | 1.2B | 947.5M | 822.4M | 808.2M | |
| Total Current Assets | 13.7B | 14.7B | 15.5B | 17.6B | 18.5B | 15.5B | |
| Net Invested Capital | 13.0B | 16.2B | 18.0B | 20.6B | 22.4B | 17.5B | |
| Net Working Capital | 5.3B | 6.0B | 6.2B | 7.4B | 7.7B | 7.1B |
Huadong Medicine Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 107.2M | 68.6M | 72.5M | 125.1M | 114.9M | 120.7M | |
| Total Revenue | 35.4B | 33.7B | 34.6B | 37.7B | 40.6B | 42.7B | |
| Operating Income | 3.2B | 3.2B | 3.0B | 3.3B | 3.8B | 4.0B | |
| Cost Of Revenue | 24.1B | 22.6B | 24.0B | 25.7B | 27.5B | 28.8B | |
| Income Before Tax | 3.5B | 3.5B | 2.8B | 3.0B | 3.5B | 3.6B | |
| Net Income | 2.8B | 2.8B | 2.3B | 2.5B | 2.8B | 3.0B | |
| Income Tax Expense | 477.4M | 544.9M | 543.7M | 488.9M | 562.2M | 590.4M | |
| Minority Interest | 557.1M | 559.6M | (37.0M) | (33.4M) | (7.5M) | (7.2M) | |
| Research Development | 1.1B | 926.7M | 979.6M | 1.0B | 1.3B | 809.4M | |
| Gross Profit | 11.4B | 11.1B | 10.6B | 12.0B | 13.2B | 10.5B | |
| Ebit | 3.2B | 3.0B | 2.8B | 3.2B | 3.6B | 2.9B | |
| Tax Provision | 544.9M | 543.7M | 488.9M | 498.5M | 619.6M | 543.9M | |
| Net Interest Income | (9.4M) | (24.2M) | (22.1M) | (43.6M) | (46.8M) | (49.2M) | |
| Interest Income | 30.6M | 61.0M | 80.4M | 103.4M | 94.0M | 64.0M | |
| Ebitda | 4.0B | 4.0B | 3.5B | 3.9B | 4.4B | 3.9B |
Huadong Medicine Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Huadong Medicine. It measures of how well Huadong is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Huadong Medicine brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Huadong had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Huadong Medicine has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Dividends Paid | 570.6M | 565.7M | 460.1M | 576.5M | 594.2M | 354.3M | |
| Capital Expenditures | 1.4B | 1.5B | 819.1M | 1.2B | 1.6B | 1.7B | |
| Net Income | 2.8B | 2.8B | 2.3B | 2.5B | 2.8B | 3.0B | |
| Change To Inventory | (159.6M) | (37.7M) | 18.1M | (491.5M) | 213.8M | 224.5M | |
| Investments | (256.9M) | (629.8M) | (357.5M) | (948.9M) | (1.8B) | (1.7B) | |
| Change In Cash | (166.9M) | 925.6M | 422.7M | (163.2M) | 791.2M | 830.8M | |
| Net Borrowings | 28.0M | (67.2M) | (146.0M) | 322.1M | 370.4M | 389.0M | |
| Depreciation | 404.5M | 431.0M | 591.6M | 698.3M | 809.6M | 476.0M | |
| Change To Netincome | 117.9M | (109.4M) | 235.2M | 290.1M | 261.1M | 142.3M | |
| End Period Cash Flow | 2.2B | 3.2B | 3.6B | 3.4B | 4.2B | 3.3B | |
| Free Cash Flow | 648.3M | 1.9B | 2.4B | 1.2B | 2.3B | 1.7B | |
| Other Non Cash Items | 111.3M | 94.1M | 90.3M | 107.0M | 116.9M | 112.0M |
Huadong Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Huadong Medicine's current stock value. Our valuation model uses many indicators to compare Huadong Medicine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Huadong Medicine competition to find correlations between indicators driving Huadong Medicine's intrinsic value. More Info.Huadong Medicine Co is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.45 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Huadong Medicine Co is roughly 2.20 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Huadong Medicine by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Huadong Medicine's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Huadong Medicine Systematic Risk
Huadong Medicine's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Huadong Medicine volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Huadong Medicine correlated with the market. If Beta is less than 0 Huadong Medicine generally moves in the opposite direction as compared to the market. If Huadong Medicine Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Huadong Medicine is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Huadong Medicine is generally in the same direction as the market. If Beta > 1 Huadong Medicine moves generally in the same direction as, but more than the movement of the benchmark.
Huadong Medicine Co Total Assets Over Time
Huadong Medicine December 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Huadong Medicine help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Huadong Medicine Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Huadong Medicine Co based on widely used predictive technical indicators. In general, we focus on analyzing Huadong Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Huadong Medicine's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.38 | |||
| Information Ratio | 0.1518 | |||
| Maximum Drawdown | 15.65 | |||
| Value At Risk | (2.94) | |||
| Potential Upside | 4.4 |
Complementary Tools for Huadong Stock analysis
When running Huadong Medicine's price analysis, check to measure Huadong Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Huadong Medicine is operating at the current time. Most of Huadong Medicine's value examination focuses on studying past and present price action to predict the probability of Huadong Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Huadong Medicine's price. Additionally, you may evaluate how the addition of Huadong Medicine to your portfolios can decrease your overall portfolio volatility.
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Commodity Directory Find actively traded commodities issued by global exchanges |